"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Novo Nordisk, the maker of Ozempic and Wegovy, is predicted to lose billions in profits due to a minor billing error in ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

WEIGHT loss jabs, including Mounjaro and Wegovy, have been linked to more than 100 deaths in the UK, new figures have revealed. But none of the fatalities are proven to have been caused directly ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Bezons (France), June 17, 2025 - 6:00pm (CET) - RIBER, the global leader in Molecular Beam Epitaxy (MBE) equipment for the semiconductor industry, announces the signing of a three-year collaborative ...

Some blind vision loss cases have been linked to the use of weight-loss jabs, including Ozempic, so caution is recommended by ...